MANSFIELD, Mass.--(BUSINESS WIRE)--Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that it will launch the TurboHawk™ Plaque Excision System for small vessels next month in the United States and several international markets. The new system is intended to treat calcified and non-calcified lesion morphologies in small vessels, broadening minimally-invasive treatment options for Peripheral Arterial Disease (PAD). The device received 510(k) clearance from the U.S. Food and Drug Administration in January.
